Glucocorticoid-induced osteoporosis: treatment options and guidelines.
Glucocorticoid-induced osteoporosis and fractures are the most frequent adverse effects of this class of medication. Recent advances in the pathophysiology, epidemiology, detection, and prevention of this complication of therapy provide hope for its amelioration in patients who require treatment with glucocorticoids. A number of effective pharmacologic agents are available and/or under study, and scientific organizations now provide guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Unfortunately, consistent application of these guidelines remains suboptimal in many practice settings.
Maricic
Michael
M
Southern Arizona VA Health Care System, 3601 S. 6th Avenue, Tucson, AZ 85723, USA. michael.maricic@med.va.gov
D019386:Alendronate / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption; D004164:Diphosphonates / Q000627:therapeutic use; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D015444:Exercise; D005260:Female; D050723:Fractures, Bone / Q000139:chemically induced; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D019983:Guideline Adherence; D006801:Humans; D008297:Male; D010012:Osteogenesis / Q000187:drug effects; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control; D010281:Parathyroid Hormone / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D000068296:Risedronic Acid
D004164:Diphosphonates; D005938:Glucocorticoids; D010281:Parathyroid Hormone; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate